Overview
Joined Fengrui Capital in 2015, focusing on investment in technology and medical care and in charge of the financial and legal department. Representative projects include Xingeyuan, Yanming Biotech, Changmugu Medical, Cayudi Biotech, Yinshi Robotics, Dingou Biotech, Nordson Chuanglian, Leao Medical, Novita, and Jiahua Yaorui. Before joining Fengrui Capital, he had more than 10 years of experience in management consulting for biomedical companies in the United States and multinational companies, commercialization of pharmaceutical and diagnostic companies, and as a technology partner in start-up companies. He holds an MBA in Healthcare from Boston University and a PhD in Physiology and Molecular Biology from the University of Notre Dame. 2025 was rated as "2024 Most Potential Female Direct Investment Fund Investors TOP" by the Fund of Funds Research Center, "S 2024 Female Investors" in ZeroIPO Entrepreneurship-Investment Circle, and was selected as "2025" by the Investor Network List of the 38 Best Female Investors", and won the "50 Outstanding Medical and Health Investors of the Year TOP" by CHC Medical Consulting & CITIC Securities (20, 2024, 50).
Sources · 0Sources & provenance
English text is maintained separately from the original record. Consult the original source before citing a fact.
No source links are available for this profile.
Original source text
Names may use phonetic renderings when no English name is supplied. The original wording is retained below.
2015年加入峰瑞资本，侧重于科技医疗方向的投资并分管财法部门的工作。代表项目包括新格元、炎明生物、长木谷医疗、卡尤迪生物、因时机器人、鼎瓯生物、诺信创联、乐奥医疗、Novita、嘉华药锐。加入峰瑞资本之前，有超过10年的美国和跨国公司生物医药企业管理咨询、制药和诊断企业商业化，以及初创企业科技合伙人的经验。拥有波士顿大学医疗事业工商管理硕士学位、美国圣母大学生理和分子生物学博士学位。2025年获评母基金研究中心「2024最具潜力女性直投基金投资人TOP20」、清科创业-投资界「S50 2024女性投资人」，入选投资家网「2025 38位最佳女性投资人榜单」，荣获CHC医疗咨询&中信证券「2024年度医疗健康卓越投资人TOP50」等。